Barclays PLC Blueprint Medicines Corp Call Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $6.86 Million - $8.76 Million	80,500 Added 77.48%	184,400 $19.9 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $4.34 Million - $5.92 Million	59,300 Added 132.96%	103,900 $9.86 Million
Q4 2023 Feb 15, 2024	BUY	$43.96 - $92.84 $1.96 Million - $4.14 Million	44,600 New	44,600 $4.11 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $2.79 Million - $3.72 Million	38,000 Added 3166.67%	39,200 $3.7 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $1.4 Million - $2.49 Million	-28,800 Reduced 96.0%	1,200 $96,000
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $1.77 Million - $2.35 Million	30,000 New	30,000 $2.34 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.